Abstract: Compositions and methods are provided for silencing the Sulf2 and/or GPC3 genes in vivo. Potent siRNA sequences are provided that silence regions of the Sulf2 and GPC3 genes that are identical in human, mice and non-human primates. Combinations of siRNAs also are provided that result in additivity or synergy with silencing of Sulf2 and/or GPC3. Silencing SULF2+TGF?1 showed a dramatic effect against cancer growth in vitro and in vivo.

Abstract: The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoA) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.

Abstract: A seamed press felt formed from a base fabric having a CD width and an MD length with two opposing MD ends that are joined to form a continuous belt. MD oriented yarns form uniform loops at the two opposing MD ends that are interdigitated to define a pintle channel extending across the CD width. CD oriented yarns are connected to the MD oriented yarns, in a woven or non-woven construction. Loop open spaces are located within the loops on each of the two opposing MD ends in a seam region, with the loop open spaces being defined between a last one of the CD yarns at each of the two opposing MD ends and the pintle channel. At least one CD monofilament support yarn is located in the loop open spaces on each of the two opposing MD ends. The at least one CD monofilament support yarn has a diameter that is at least 1.6 times a diameter of the CD oriented yarns. A pintle extends through the pintle channel to form a seam.

Abstract: Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.

Abstract: The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.

Abstract: The current invention provides a method of activating fibroblast and myofibroblast apoptosis in a tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGFB1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine polymer. The invention also provides additional methods for using this composition.

Abstract: The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.

Abstract: The present disclosure relates to abrasive articles that include abrasive aggregates of silicon carbide with a vitrified bond, and methods of making and using such abrasive articles and abrasive aggregates. In particular, the abrasive aggregates can possess a combination of beneficial properties and comprise a vitreous binder composition having a specific composition, sintering temperature, glass transition temperature, or a combination thereof.

Abstract: The present invention provides small interfering RNA (siRNA) molecules, compositions containing the molecules, and methods of using the molecules and compositions to treat breast cancer. In one aspect, a multi-targeted siRNAi cocktail is disclosed. The siRNA molecules may be encapsulated in nanoparticles to further enhance their anti-cancer activity. The compositions may also be used in combination with other anti-cancer agents, such as bevacizumab.

Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.

Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.

Abstract: The present invention provides small interfering RNA (siRNA) molecules, compositions containing the molecules, and methods of using the molecules and compositions to treat breast cancer. In one aspect, a multi-targeted siRNAi cocktail is disclosed. The siRNA molecules may be encapsulated in nanoparticles to further enhance their anti-cancer activity. The compositions may also be used in combination with other anti-cancer agents, such as bevacizumab.

Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.

Abstract: The present disclosure provides transgenic seeds and plants with enhanced cold tolerance and cold vigor. The disclosure also provides methods of producing these transgenic plants and seeds. The present disclosure further provides methods of producing crops that can be grown under sub-optimum conditions and methods of increasing the yield of crop plants by extending growing season of a plant by earlier planting of transgenic seeds of the invention under sub-optimum growth conditions.

Abstract: A method and apparatus for conducting secured multicast in an asynchronous transfer mode based passive optical network communication (“APON”) system having a central network device, such as an optical line terminal (“OLT”), and multiple network devices, such as optical network terminals (“ONT”), whereby the central network device communicates with the network devices using multicast encryption key that is selected or generated from among the churning keys belonging to the network devices, and whereby the central network device periodically updates the multicast encryption key by delivering to the network devices the difference values between the updated multicast encryption key and the respective churning key of each network device.

Abstract: A method and apparatus for protecting faults in an optical network. Protection is based on 1:n protection at an Optical Line Terminator (“OLT”). Each working interface module in the OLT is coupled via a fiber to a 2:N splitter which provides communication with N Optical Network Units (“ONU”). A protection interface module is coupled via a fiber to a 1:n switch whose output is coupled to each of the 2:N splitters. In the event of a fiber break, protection switching is performed by forming a backup link to the 2:N splitter associated with the failed fiber through the protection interface module. The 1:n protection arrangement may be replicated and extended to a g*(1:n) protection arrangement. A uni-ranging process speeds up protection switching by ranging only one ONU associated with a failed fiber, rather than all ONUs associated with a failed fiber.

Abstract: A system for processing data is provided. The system includes a data type detector that determines whether a data frame is a speech/voice data frame or a data/fax data frame. The system further includes a transcoder and rate adapter system that is connected to the data type detector. The data type detector transfers the data frame to the transcoder and rate adapter system if the data frame is a voice data frame. An interworking function system is also connected to the data type detector. The data type detector transfers the data frame to the interworking function system if the data frame is a data/fax data frame.

Abstract: A method for processing telecommunications data is provided. The method includes receiving telecommunications data, such as at a component of a telecommunications switch. It is then determined whether the telecommunications data includes speech/voice data or data/fax data. Transcoder and rate adaption processing is performed on the telecommunications data with signal processing circuitry if the telecommunications data is speech/voice data. Otherwise, interworking function processing is performed on the telecommunications data with the signal processing circuitry if the telecommunications data is data/fax data.